Schizophrenia is a chronic and severe mental disorder characterized by profound interruptions in thought processes, perceptions, emotional responsiveness, and social interactions. Additionally, it can also impair functioning through the loss of an acquired capability to earn a livelihood or the disruption of studies. It is a chronic brain disorder that affects less than 1% of the U.S. population. When schizophrenia is active, symptoms can include delusions, hallucinations, trouble with thinking and concentration, and lack of motivation.
As per the “World Health Organization (WHO)”, research has not identified one single factor for the cause of Schizophrenia. It is thought that interaction between genes and a range of environmental factors may cause schizophrenia. Psychosocial factors may also contribute to Schizophrenia.
Get FREE sample copy at:
https://www.delveinsight.com/sample-request/schizophrenia-market
The Schizophrenia market report also covers emerging drugs, current treatment practices, Schizophrenia market share of the individual therapies, current and forecasted Schizophrenia Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Schizophrenia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Schizophrenia Market Key Facts
-
According to the World Health Organization, Schizophrenia is a chronic and severe mental disorder affecting 20 million people worldwide. In addition, people with Schizophrenia are 2-3 times more likely to die early than the general population. This is often due to preventable physical diseases, such as cardiovascular disease, metabolic disease, and infections.
-
According to “Division of Mental Health and Prevention of Substance Abuse, WHO”, the point prevalence on adults ranges between 1 and 17 per 1000 population, one-year prevalence between 1 and 7.5 per 1000, and lifetime prevalence between 1 and 18 per 1000. Schizophrenia also commonly starts earlier among men.
-
According to the World Health Organization, Schizophrenia is more common among males than females.
-
The “National Institute of Mental Health” estimated that the prevalence of schizophrenia and related psychotic disorders in the United States range between 0.25% and 0.64%.
-
According to “Schizophrenia Society of Saskatchewan”, the illness most frequently occurs in the 16 – 30-year-old age group. It can also appear later in adulthood. However, onset after the age of 35 is less common and after the age of 40 is rare.
Key Benefits of Schizophrenia Market Report
-
Schizophrenia market report provides an in-depth analysis of Schizophrenia Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.
-
The Schizophrenia market report will help in developing business strategies by understanding the Schizophrenia Market trends & developments, key players, and future market competition that will shape and drive the Schizophrenia market in the upcoming years.
-
The Schizophrenia market report covers Schizophrenia’s current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
-
The report provides a detailed assessment of the Schizophrenia market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
The Schizophrenia market outlook section of the report helps to build a detailed comprehension of the historic, current and forecasted Schizophrenia market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Schizophrenia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Schizophrenia Epidemiology
The Schizophrenia epidemiology section covers insights about the historical and current Schizophrenia patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Schizophrenia Drugs Uptake and Key Market Players
The Schizophrenia Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Schizophrenia market or expected to get launched in the market during the study period. The analysis covers Schizophrenia market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The dynamics of the Schizophrenia market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the disease, incremental healthcare spending across the world, and the expected launch of emerging therapies during the forecast period. The pipeline of Schizophrenia is highly robust involving several investigative trials being carried out.
Schizophrenia Companies:
GW Pharmaceuticals
Avanir Pharmaceuticals
Minerva Neurosciences
Karuna Therapeutics
Sunovion
Concert Pharmaceuticals
SyneuRx International
Otsuka
And many others.
Schizophrenia Therapies covered in the report include:
GWP42002/GWP42003
AVP-786
Roluperidone
KarXT
SEP-363856
CTP-692
NaBen
Rexulti (Brexpiprazole)
And many more.
Table of Content
1. Key Insights
2. Executive Summary
3. Schizophrenia Competitive Intelligence Analysis
4. Schizophrenia Market Overview at a Glance
5. Schizophrenia Disease Background and Overview
6. Schizophrenia Patient Journey
7. Schizophrenia Epidemiology and Patient Population
8. Schizophrenia Treatment Algorithm, Current Treatment, and Medical Practices
9. Schizophrenia Unmet Needs
10. Key Endpoints of Schizophrenia Treatment
11. Schizophrenia Marketed Products
12. Schizophrenia Emerging Therapies
13. Schizophrenia Seven Major Market Analysis
14. Attribute Analysis
15. Schizophrenia Market Outlook (7 major markets)
16. Schizophrenia Access and Reimbursement Overview
17. KOL Views on the Schizophrenia Market.
18. Schizophrenia Market Drivers
19. Schizophrenia Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Related Reports
Schizophrenia Pipeline Insights
Schizophrenia Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Schizophrenia market.
BioPharma Blog – Obesity Risk Factors and Therapeutics Market
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd. 2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/